Investor Recommends Celera Spin Out Merck Royalty Asset | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – An investment fund has filed a document with the US Securities and Exchange Commission recommending that Celera spin out, segregate, or distribute its royalty asset that is associated with a Merck drug candidate currently in Phase III studies.

Biotechnology Value Fund filed the Schedule 13D two days ago. The fund and its affiliates own nearly 10 percent of Celera's 81.9 million shares outstanding, as of its last 10-Q, which was filed with the SEC on Nov. 9, 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.